Anti-CD19 Anti-CD20 bispecific chimeric antigen receptor T cell therapeutics(Beijing Doing Biomedical)

N/A

Report date: 2024/11/11 20:00:37

Base Information

Drug NameAnti-CD19 Anti-CD20 bispecific chimeric antigen receptor T cell therapeutics(Beijing Doing Biomedical)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity

TargetsNot applicable

Therapy Area/IndicationsLymphomaLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaPending

Originator CompaniesBeijing Doing Biomedical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBeijing Doing Biomedical Co Ltd

Active IndicationsN/A

Inactive IndicationsLymphomaLeukemia

Other Information

ATC CodeN/A